[Investigation of antimycotic susceptibility of Candida krusei clinical isolates from pulmonary tuberculosis patients].
The results of the laboratory diagnosis of secondary infections of the bronchi and lungs due to Candida krusei strains isolated from patients with respiratory tract tuberculosis are presented. The activity of fluconazole, amphothericin B, itraconazole, ketoconazole, myconazole and 5-fluorocytosin against the C. krusei isolates from a tuberculosis clinic within 2003-2008 was tested. A decrease in the number of the C. krusei isolates susceptible to fluconazole from 30% in 2003 to 0% in 2008 was recorded.
A B
AB
Kul'ko
D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000254:growth & development* / Q000302:isolation & purification; D025141:Drug Resistance, Fungal / Q000187:drug effects; D005260:Female; D006801:Humans; D008168:Lung / Q000382:microbiology*; D008297:Male; D008826:Microbial Sensitivity Tests; D012189:Retrospective Studies; D014376:Tuberculosis / Q000382:microbiology*
D000935:Antifungal Agents